The pathogenesis of hidradenitis suppurativa (HS) remains to be fully elucidated. Seminal clinical and translational investigations from the preceding 10 years have highlighted substantial variability in the contributors...The pathogenesis of hidradenitis suppurativa (HS) remains to be fully elucidated. Seminal clinical and translational investigations from the preceding 10 years have highlighted substantial variability in the contributors to inflammatory pathways involved in HS. These span from hormonal, metabolic, and microbial to genetic factors, each with potential flow on effects on immune cell polarization and subsequent clinically apparent inflammation. Understanding the heterogeneous drivers of HS and its progression may empower clinicians to take a more holistic approach in treatment planning, including addressing inflammatory comorbidities; therapeutic selection based on clinicopathological biomarkers; and appropriate patient counseling.
Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory disease that results in painful nodules, abscess, and draining tunnels which eventuate in morbid scarring. Patients with HS are at risk for various cu...Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory disease that results in painful nodules, abscess, and draining tunnels which eventuate in morbid scarring. Patients with HS are at risk for various cutaneous and systemic comorbid diseases including inflammatory bowel disease, cardiovascular, endocrine, and psychiatric conditions. Given its high symptom burden, chronic and progressive course, and association with comorbid conditions, HS has a profound life impact on patients.
Hidradenitis suppurativa (HS) is a chronic inflammatory disorder with a heterogeneous phenotype. HS is a recurrent, fluctuating disease with various natural histories. Its phenotypes have been associated with responses t...Hidradenitis suppurativa (HS) is a chronic inflammatory disorder with a heterogeneous phenotype. HS is a recurrent, fluctuating disease with various natural histories. Its phenotypes have been associated with responses to therapy; however, more studies about treatment response are needed, as is evaluation of biomarkers, before conclusions can be reached. This article provides a scoping review of HS phenotypes reported in the literature, with the hope that the results may offer insights for a more individualized approach to treatment.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful skin abscesses, fistulizing sinus tracts, and scarring. Despite its devastating negative effects on patients' health, qualit...Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful skin abscesses, fistulizing sinus tracts, and scarring. Despite its devastating negative effects on patients' health, quality of life, performance, and mental health, HS epidemiology is not well understood. This study aims to better characterize the epidemiology of HS, including incidence, prevalence, various demographic distributions, and risk factors. This can further the understanding of HS disease development and improve recognition, diagnosis, and treatment.
This comprehensive review article gives an up-to-date assessment of the therapeutic landscape for warts and molluscum contagiosum (MC), focusing on advances made in the last 5 years. New treatment choices include VP-102...This comprehensive review article gives an up-to-date assessment of the therapeutic landscape for warts and molluscum contagiosum (MC), focusing on advances made in the last 5 years. New treatment choices include VP-102 (Ycanth) for molluscum contagiosum, potentially intralesional Vitamin D3 for warts, and topical cidofovir for both. Immunotherapy is regarded as a potential option, especially in difficult situations. Traditional therapies like cryotherapy and keratolytic medicines remain the principal options. The study emphasizes the need for personalized treatment strategies and additional research to improve therapy efficacy and safety.
This review discusses recent progress in actinic keratosis (AK) management, highlighting therapeutic breakthroughs, pathophysiological discoveries, and program implementation strategies. This article also explores advanc...This review discusses recent progress in actinic keratosis (AK) management, highlighting therapeutic breakthroughs, pathophysiological discoveries, and program implementation strategies. This article also explores advances in photodynamic therapy, introduces new topical treatments, and details the genomic and transcriptomic pathways from AK to squamous cell carcinoma, including the role of the cutaneous microbiome. Studies aiming to improve diagnosis, adherence, and patient-focused care are also reviewed. Together, these insights encourage a move toward personalized, technology-enhanced approaches in AK treatment, aiming to better patient outcomes and prevent the escalation to more severe skin cancers.
Vitiligo is a chronic skin condition characterized by the loss of melanocytes, resulting in white patches on the skin. While its exact cause is unknown, it's believed to be an autoimmune disorder involving genetic, envir...Vitiligo is a chronic skin condition characterized by the loss of melanocytes, resulting in white patches on the skin. While its exact cause is unknown, it's believed to be an autoimmune disorder involving genetic, environmental, and immunologic factors. Various treatments, including topical drugs, phototherapy, and surgery, exist, but further research is needed for more targeted therapies. Standardization of treatment goals and outcome measures is crucial. Future directions involve personalized treatments based on genetic and immunologic profiles, along with advancements in melanocyte biology for more effective therapies. Collaborative research is the key to improving outcomes and quality of life for vitiligo patients.
This study aims to analyze and discuss recent trials of high-dose and liquid toxins for treating moderate to severe glabellar lines. A comprehensive review of clinical studies and patient outcomes data was conducted to a...This study aims to analyze and discuss recent trials of high-dose and liquid toxins for treating moderate to severe glabellar lines. A comprehensive review of clinical studies and patient outcomes data was conducted to assess the effectiveness and safety profiles of high-dose and liquid toxins. Clinical studies have demonstrated that high-dose toxins provide prolonged muscle relaxation and reduced wrinkles, with well-tolerated safety profiles. Liquid toxins offer comparable efficacy to traditional formulations with quicker onset and extended duration of effects. The introduction of high-dose and liquid toxins represents a significant advancement in esthetic medicine, providing patients with more options for achieving natural-looking, long-lasting results.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful, recurrent abscesses, inflammatory nodules, and draining tunnels. Biologic and small molecule therapeutics are effective for...Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful, recurrent abscesses, inflammatory nodules, and draining tunnels. Biologic and small molecule therapeutics are effective for treatment of moderate-to-severe HS. The field of HS is rapidly growing with numerous ongoing clinical trials exploring novel agents. This review highlights the latest discoveries in the field of HS, with a particular focus on novel therapeutic agents and procedural management.
Advances in understanding of AA have led to the first approved therapies for this disease, and in the past two years, there have been three medicines approved for the treatment of severe alopecia areata. There are numero...Advances in understanding of AA have led to the first approved therapies for this disease, and in the past two years, there have been three medicines approved for the treatment of severe alopecia areata. There are numerous clinical trials of novel therapeutics underway across the spectrum of AA.
Laser-based therapies show expanding utility in treating various medical conditions. Despite their efficacy, limited insurance coverage hinders accessibility due to high costs, deterring patients. Integrating lasers with...Laser-based therapies show expanding utility in treating various medical conditions. Despite their efficacy, limited insurance coverage hinders accessibility due to high costs, deterring patients. Integrating lasers with systemic and topical treatments can revolutionize dermatologic care, offering viable alternatives for numerous conditions.
Cutaneous lupus erythematosus (CLE) is an autoimmune-mediated skin disease under the family of lupus erythematosus. Systemic immunosuppressants and topical treatments have been used to manage CLE; however, these treatmen...Cutaneous lupus erythematosus (CLE) is an autoimmune-mediated skin disease under the family of lupus erythematosus. Systemic immunosuppressants and topical treatments have been used to manage CLE; however, these treatments tend to be moderately efficacious and leave patients with unmet therapeutic needs. There is a need for medications that target pruritus, scarring, dyspigmentation, and other symptoms of chronic CLE that contribute to decreased quality of life. The introduction of new biologics and other systemic medications has expanded dermatologists' and rheumatologists' ability to manage CLE. This article discusses new pharmaceuticals and guidelines providing an updated overview of the clinical management of CLE.
Photoprotection remains the foundation of treatment for all dyschromias and cosmetic camouflage as it provides concealment of pigmentation until therapeutic agents are effective. Innovations in the treatment of dyschromi...Photoprotection remains the foundation of treatment for all dyschromias and cosmetic camouflage as it provides concealment of pigmentation until therapeutic agents are effective. Innovations in the treatment of dyschromias encompass topical, systemic, and procedural modalities.
Although many treatments are available for acne, these can be limited by lack of effectiveness, patient tolerance and adherence, and accessibility. This review provides a comprehensive summary of the latest developments...Although many treatments are available for acne, these can be limited by lack of effectiveness, patient tolerance and adherence, and accessibility. This review provides a comprehensive summary of the latest developments in acne management, exploring a range of topical, systemic, and procedural treatments. The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals. The clinical pipeline is also summarized. In addition, opportunities to improve the patient experience with spironolactone and isotretinoin are discussed.
Dermatomyositis (DM) is a rare autoimmune disease defined by the presence of characteristic cutaneous findings, an increased cancer risk, and variable extracutaneous pathology involving the muscles, lungs, gastrointestin...Dermatomyositis (DM) is a rare autoimmune disease defined by the presence of characteristic cutaneous findings, an increased cancer risk, and variable extracutaneous pathology involving the muscles, lungs, gastrointestinal tract, heart, and/or joints. Although the pathogenesis of DM remains incompletely understood, the discovery of myositis-specific autoantibodies has been an important step forward in understanding disease heterogeneity in DM and stratifying risk for extracutaneous disease and malignancy. Moreover, the recent elucidation of key immunologic drivers of DM has laid the groundwork for the development of novel, targeted treatments in the DM therapeutic pipeline.
Despite numerous effective biologics for treating psoriasis, new treatments continue to be investigated due to an unmet need for certain patient populations. This review discusses therapies that were recently Food and Dr...Despite numerous effective biologics for treating psoriasis, new treatments continue to be investigated due to an unmet need for certain patient populations. This review discusses therapies that were recently Food and Drug Administration (FDA)-approved for treating psoriasis, including the topical agents tapinarof and roflumilast, deucravacitinib, an oral small molecule that selectively inhibits tyrosine kinase 2, and spesolimab, a monoclonal antibody inhibiting interleukin-36 that became the first FDA-approved treatment for generalized pustular psoriasis flares. Other therapies are in the pipeline, such as orismilast, as well as Mind.Px, a tool for predicting biological response, is also highlighted.
Atopic dermatitis (AD) is a multi-system inflammatory skin disorder with early onset in the skin. It is well known that Black and Hispanic children in the United States experience specific barriers in regards to accessin...Atopic dermatitis (AD) is a multi-system inflammatory skin disorder with early onset in the skin. It is well known that Black and Hispanic children in the United States experience specific barriers in regards to accessing care for AD, including greater severity on presentation and more need for care including increased usage of emergency services. Understanding these social determinants is vital if social change is to be made and if policies are to be constructed to create enduring reductions in disparity in a meaningful way that can potentially level disease severity and access to care for all segments of the family.
Atopic dermatitis (AD) is a prevalent dermatologic condition affecting both children and adults, and the debate surrounding its association as either a risk or protective factor for malignancies has garnered significant...Atopic dermatitis (AD) is a prevalent dermatologic condition affecting both children and adults, and the debate surrounding its association as either a risk or protective factor for malignancies has garnered significant attention. Proposed mechanisms suggest that AD may act protectively against cancer formation through chronic immune system activation or create an inflammatory state conducive to cancer development. This review discusses the relationship between AD and various skin cancers, solid tumors, and hematologic malignancies. Additionally, the authors explore the impact of AD treatments, particularly novel biologic drugs targeting molecular pathways such as JAK-STAT, IL-4, and IL-13 in association with malignancies.